SpectraScience’s WavSTAT OBS Highlighted in Presentations at Digestive Disease Week
Research data shows effectiveness in diagnosing esophageal and colorectal cancer
SAN DIEGO, May 24, 2012 (MARKETWIRE) – Presentations at the recently concluded Digestive Disease Week Conference (DDW) in San Diego featured positive data on the ability of the SpectraScience (OTCPK: SCIE) WavSTAT4 Optical Biopsy System to diagnose early stage colorectal and esophageal cancer. “We are very encouraged by the research results presented during DDW and by the discussions we had with physicians throughout the conference,” said SpectraScience’s Chief Executive Officer Michael Oliver. “I believe these studies and the ongoing research with the Optical Biopsy System can support our commercialization efforts now underway in Europe.”
In a live presentation titled “Fluorescence Spectroscopy Incorporated in an Optical Biopsy System (OBS) for the Detection of Early Neoplasia in Barrett's Esophagus (BE),” Dr. David Boerwinkel from the Department of Gastroenterology and Hepatology at the Academic Medical Center (AMC) in Amsterdam provided results of endoscopies on 32 patients with Barrett’s esophagus in which areas suspicious for neoplasia and endoscopically inconspicuous areas were collected with the WavSTAT OBS, followed by a correlating physical biopsy with the optical biopsy forceps for histological evaluation.
“This feasibility study shows that the WavSTAT OBS is able to distinguish non-dysplastic Barrett’s mucosa from high grade intraepithelial neoplasia (HGIN) or early cancer (EC) at early stage,” said Dr. Boerwinkel. “The WavSTAT Optical Biopsy forceps is a great tool for future spectroscopy studies given the optimal tissue correlation, and the OBS may aid the endoscopist during surveillance endoscopy for early Barrett’s neoplasia and improve surveillance efficacy.” The Academic Medical Center is performing additional data acquisition to further optimize WavSTAT’s diagnostic algorithm, which will be followed by a prospective validation study to investigate the value of the WavSTAT-OBS during surveillance of BE patients.
In a separate poster presentation titled “Differentiation of Small Colorectal Lesions; Laser-Induced Autofluorescence Using the WavSTAT,” a team of researchers from AMC reported on a current studyassessing the performance of an algorithm combining white light (WL) in high confidence lesions and WavSTAT in low confidence lesions. The algorithm, in which WavSTAT replaces WL in low confidence lesions, improved overall sensitivity compared to WL alone from 70% to 85%. Results of using the WavSTAT as an adjunctive tool increased the clinical sensitivity to distinguish an adenoma from a hyperplastic polyp by 20.7%. In addition, the negative predictive value of using the WavSTAT was improved by 15% as compared to the endoscopist and high- resolution endoscopy (HRE) alone.
About SpectraScience, Inc.
SpectraScience is a San Diego based medical device company that designs, develops, manufactures and markets light-based analysis systems capable of determining whether tissue is normal, pre-cancerous or cancerous without physically removing tissue from the body. The WavSTAT Optical Biopsy System uses light to optically diagnose tissue and provide the physician with an immediate analysis. With the CE Mark approval for sale in the European Union, the WavSTAT System is the first commercially available product that incorporates this innovative technology for clinical use.
About Digestive Disease Week
Digestive Disease Week is the world’s largest gathering of physicians and researchers in the fields of gastroenterology, hepatology, endoscopy, and gastrointestinal surgery. The conference is jointly sponsored by four societies: the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterological Association (AGA) Institute, the American Society for Gastrointestinal Endoscopy (ASGE) and the Society for Surgery of the Alimentary Tract (SSAT).
Forward Looking Statements
This news release contains statements of a forward-looking nature which represent management's beliefs and assumptions concerning future events. When used in this presentation, the words “believe,” “expect,” and similar expressions are intended to identify forward-looking statements, including statements regarding commercialization of the WavSTAT Optical Biopsy System. Forward-looking statements involve risks, uncertainties and assumptions, and are based on information currently available to us. Actual results may differ materially from those expressed in the forward-looking statements due to many factors, including, without limitation, those disclosed under “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2011 and our quarterly reports on Form 10-Q. We undertake no obligation to update any forward-looking statements to reflect events or circumstances that may arise after the date of this news release.
Jim Dorst, Chief Financial Officer